Lisata Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.0M
- Price
- $1.55
- % Change (Daily % change from the live per-ticker quote feed.)
- +38.39%
- Volume
- 7.1M
About
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Quick stats
Shares outstanding9.0M
Computed float7.2M
Float / shares79.9%
Cash runway (months)7.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000320017
Websitehttps://www.lisata.com
AI Summary
AI-generated1/21
majorbearishlegal litigation
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Lisata Therapeutics terminated its merger agreement with Kuva Labs and filed suit in the Delaware Court of Chancery seeking a $2 million termination fee and damages for breach of contract.
The board is evaluating strategic alternatives including potential liquidation or dissolution, alongside acquisitions or asset sales.
To preserve cash, the company implemented a reduction in force of approximately 72% of full-time employees, eliminating the Executive Vice President of R&D and Chief Medical Officer positions.
Red flags
- strategic alternatives include liquidation and dissolution
- reduction in force of approximately 72%
- elimination of Executive Vice President of R&D and Chief Medical Officer roles
- merger agreement terminated and sued for breach